# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $100 pri...
Needham analyst Gil Blum maintains Immunocore Hldgs (NASDAQ:IMCR) with a Buy and lowers the price target from $81 to $78.
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancerBrenetafu...
Cantor Fitzgerald analyst Eric Schmidt reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Overweight.
Di Donato has accepted the role of Chief Executive Officer at a private, early-stage biotech headquartered in San Diego, Califo...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $100 pri...